Pontifax Management 4 G.P. (2015) Ltd. - 15 Oct 2025 SCHEDULE 13D/A Report for Keros Therapeutics, Inc. Common Stock, Par Value $0.0001 Per Share (KROS)

Filing Manager
Pontifax Management 4 G.P. (2015) Ltd.
Reporting Manager
Pontifax Management 4 GP (2015) Ltd.
Security
Keros Therapeutics, Inc. Common Stock, Par Value $0.0001 Per Share
Symbol
KROS
Disclosed Ownership
0 shares
Ownership
0%
Form type
SCHEDULE 13D/A
Filing time
16 Oct 2025, 17:36:49 UTC
Date of event
15 Oct 2025
Previous filing
18 Apr 2025
SEC
View on sec.gov

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Pontifax Management 4 GP (2015) Ltd. 0% 0 0 0 /s/ Tomer Kariv Tomer Kariv, Chief Executive Officer 0001726334
Pontifax (Israel) IV, L.P. 0% 0 0 0 /s/ Tomer Kariv Tomer Kariv, Chief Executive Officer
Pontifax (Cayman) IV, L.P. 0% 0 0 0 /s/ Tomer Kariv Tomer Kariv, Chief Executive Officer
Pontifax (China) IV, L.P. 0% 0 0 0 /s/ Tomer Kariv Tomer Kariv, Chief Executive Officer
Pontifax Late Stage Fund L.P. 0% 0 0 0 /s/ Asaf Shinar Asaf Shinar, Chief Financial Officer
Pontifax Late Stage GP Ltd. 0% 0 0 0 /s/ Asaf Shinar Asaf Shinar, Chief Financial Officer